Karyopharm Therapeutics files for Chapter 11 bankruptcy in Texas
What happened
Karyopharm Therapeutics filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the Southern District of Texas. The filing is part of a Restructuring Support Agreement with lenders and stakeholders that proposes a merger between Ayrmid Ltd. and a reorganized Karyopharm Therapeutics. Karyopharm Therapeutics received a commitment of $55 million in additional financing.
From prnewswire.com
Why it matters
Karyopharm Therapeutics will continue to operate in the ordinary course of business while focusing on its multiple myeloma and myelofibrosis programs. Ayrmid Ltd. will serve as the lead bidder in the court-supervised sale process designed to maximize business value.
From prnewswire.com
Who's involved
- Karyopharm Therapeutics (United States)Pharmaceutical company filing for Chapter 11 bankruptcy and undergoing restructuring
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Karyopharm Therapeutics (United States)Speculative
Karyopharm Therapeutics might see its ownership and corporate structure fundamentally change through the court-supervised sale process
Keep exploring
The entities involved
-
Southern District
District of Botswana
-
Richard Paulson
Swedish screenwriter
Nothing else this week.